David A. Siegel Vista Gen Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.16 $18,081 - $32,144	-200,900 Reduced 85.71%	33,500 $3,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.07 $32,816 - $250,808	234,400 New	234,400 $36,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.73 $360,800 - $709,300	-410,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.14 - $2.09 $671,232 - $1.23 Million	-588,800 Reduced 58.95%	410,000 $508,000
Q4 2021 Feb 14, 2022	SELL	$1.67 - $2.76 $184,869 - $305,532	-110,700 Reduced 9.98%	998,800 $1.95 Million

Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $1.25 Million - $1.65 Million	478,500 Added 75.83%	1,109,500 $3.04 Million
Q2 2021 Aug 16, 2021	SELL	$1.96 - $3.15 $146,412 - $235,305	-74,700 Reduced 10.59%	631,000 $1.99 Million
Q1 2021 May 17, 2021	BUY	$1.89 - $2.96 $1.11 Million - $1.74 Million	587,400 Added 496.53%	705,700 $1.5 Million
Q4 2020 Feb 16, 2021	BUY	$0.65 - $1.94 $58,175 - $173,630	89,500 Added 310.76%	118,300 $230,000
Q3 2020 Nov 16, 2020	BUY	$0.48 - $1.03 $13,824 - $29,664	28,800 New	28,800 $20,000

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.